Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort159
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma159
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M143
Disparities in time to treatment with oral antimyeloma medications138
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib121
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity115
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells112
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT105
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes102
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study99
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine98
Genomic landscape of hyperleukocytic acute myeloid leukemia95
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma88
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma81
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes80
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease79
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients74
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency72
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid71
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study69
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia68
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report68
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma67
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management65
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm63
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor59
A multiparametric niche-like drug screening platform in acute myeloid leukemia58
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study57
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma53
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia50
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression49
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study48
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis47
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier46
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma45
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma44
RSK1 dependency in FLT3-ITD acute myeloid leukemia44
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma44
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia43
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome43
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment42
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review42
0.1073682308197